Astria Therapeutics (NASDAQ:ATXS) Coverage Initiated at JMP Securities

JMP Securities started coverage on shares of Astria Therapeutics (NASDAQ:ATXS) in a research report released on Friday, Marketbeat.com reports. The brokerage issued an outperform rating and a $26.00 price target on the biotechnology company’s stock.

A number of other brokerages have also recently commented on ATXS. Oppenheimer upped their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Thursday, January 23rd. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $25.67.

Astria Therapeutics Stock Up 4.9 %

Shares of ATXS stock opened at $7.86 on Friday. Astria Therapeutics has a 1 year low of $7.16 and a 1 year high of $16.90. The stock’s 50-day moving average is $8.93 and its two-hundred day moving average is $10.45.

Hedge Funds Weigh In On Astria Therapeutics

A number of large investors have recently made changes to their positions in ATXS. Rhumbline Advisers increased its holdings in Astria Therapeutics by 2.3% in the fourth quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company’s stock valued at $556,000 after buying an additional 1,381 shares in the last quarter. New York State Common Retirement Fund raised its holdings in Astria Therapeutics by 67.0% during the fourth quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 4,300 shares during the last quarter. Quest Partners LLC boosted its position in Astria Therapeutics by 180.8% during the third quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 5,798 shares in the last quarter. SG Americas Securities LLC grew its holdings in Astria Therapeutics by 51.3% in the fourth quarter. SG Americas Securities LLC now owns 21,296 shares of the biotechnology company’s stock valued at $190,000 after purchasing an additional 7,218 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Astria Therapeutics by 8.7% in the third quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company’s stock valued at $1,624,000 after buying an additional 11,763 shares in the last quarter. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.